PubMed:18356633 / 640-837 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T5","span":{"begin":0,"end":197},"obj":"Sentence"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}

{"project":"LitCoin-entities","denotations":[{"id":"4823","span":{"begin":6,"end":14},"obj":"OrganismTaxon"},{"id":"4824","span":{"begin":50,"end":80},"obj":"DiseaseOrPhenotypicFeature"},{"id":"4825","span":{"begin":113,"end":127},"obj":"ChemicalEntity"},{"id":"4826","span":{"begin":188,"end":196},"obj":"ChemicalEntity"}],"attributes":[{"id":"A9","pred":"db_id","subj":"4823","obj":"NCBITaxon:9606"},{"id":"A10","pred":"db_id","subj":"4824","obj":"MESH:D006402"},{"id":"A11","pred":"db_id","subj":"4824","obj":"MESH:D009369"},{"id":"A12","pred":"db_id","subj":"4825","obj":"MESH:D000617"},{"id":"A13","pred":"db_id","subj":"4826","obj":"MESH:D000583"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T7","span":{"begin":170,"end":178},"obj":"GeneOrGeneProduct"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T4","span":{"begin":170,"end":178},"obj":"GeneOrGeneProduct"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T5","span":{"begin":50,"end":80},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A5","pred":"ID:","subj":"T5","obj":"DISEASE"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T4","span":{"begin":50,"end":80},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"#label","subj":"T4","obj":"DISEASE"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T8","span":{"begin":113,"end":127},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":188,"end":196},"obj":"ChemicalEntity"}],"attributes":[{"id":"A8","pred":"ID:","subj":"T8","obj":"D000617"},{"id":"A9","pred":"ID:","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_47779"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D000583"},{"id":"A11","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_2637"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":6,"end":14},"obj":"OrganismTaxon"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T10","span":{"begin":188,"end":196},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":113,"end":127},"obj":"ChemicalEntity"},{"id":"T44356","span":{"begin":50,"end":80},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T36529","span":{"begin":6,"end":14},"obj":"OrganismTaxon"}],"attributes":[{"id":"A11","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_2637"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D000583"},{"id":"A9","pred":"ID:","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_47779"},{"id":"A8","pred":"ID:","subj":"T8","obj":"D000617"},{"id":"A32761","pred":"#label","subj":"T44356","obj":"DISEASE"}],"text":"Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin."}